BioCentury | Apr 17, 2019
Emerging Company Profile

Nocion: Targeting pain neurons and nothing else

With a $27 million series A co-led by Canaan and F-Prime Capital announced Wednesday, Nocion thinks it could replace opioids in a range of tissue-localized indications, starting with cough. The company is aiming to minimize...
BioCentury | Jan 23, 2019
Distillery Therapeutics

Infectious disease

INDICATION: Zika virus Cell culture and mouse studies suggest IL-29 and IL-28A could help prevent Zika infection in women. In primary human vaginal and cervical epithelial cells, pretreatment with IL-29 decreased Zika infection compared with...
BioCentury | Aug 1, 2018
Distillery Therapeutics

Cancer

INDICATION: Lung cancer Patient sample, cell culture and mouse studies suggest inhibiting activin signaling could enhance the efficacy of platinum-based chemotherapy in KRAS-mutant lung cancer. In 59 patients with stage IV non-small cell lung cancer...
BioCentury | Jul 3, 2018
Financial News

Frazier names Caine executive partner

Frazier Healthcare Partners hired Andy Caine as an executive partner on its growth buyout team. He was a partner at Green Peak Partners. Since closing a $780 million growth buyout fund in April, Frazier has...
BioCentury | Apr 3, 2018
Targets & Mechanisms

Sensor sensibility

Zhijian “James” Chen’s discovery of the DNA sensor cGAS revealed the missing link between cytosolic DNA and innate immune activation, paving the way for immunotherapies targeting the cGAS-STING pathway. The lowest-hanging fruit has been in...
BioCentury | Dec 2, 2017
Strategy

Branching out

Decibel Therapeutics Inc. and Regeneron Pharmaceuticals Inc. have embarked on a deal that gives the smaller company a suite of technologies it could not build itself, while giving the big cap a stake in a...
BioCentury | Sep 21, 2017
Tools & Techniques

On your marks

With less fanfare than the first two waves, a quiet rise in activity is driving a revival of interest in epigenetics, despite little progress in solving the fundamental challenges that have dogged the field from...
BioCentury | Jul 7, 2017
Product Development

One small CETP for Merck

Merck & Co. Inc. ’s massive cardiovascular outcomes trial for anacetrapib finally may have shown a CETP inhibitor provides a benefit. But the question remains whether the relative risk reduction is large enough for it...
BioCentury | Jan 26, 2017
Strategy

Deep roots

Regeneron Pharmaceuticals Inc . is starting to see the fruits of its experiment with Geisinger Health System to mine vast quantities of patient data for links between genotype and phenotype. Three years into the project, the...
BioCentury | Aug 8, 2016
Emerging Company Profile

Interrogating immunity

OncoResponse Inc. is repurposing Theraclone Sciences Inc .'s I-STAR discovery platform to identify antibodies produced by exceptional responders to cancer immunotherapy. By tapping patients' natural immune responses, OncoResponse hopes to find novel immune targets and...
Items per page:
1 - 10 of 224